MOLN

2.5255.25%
KH

Ken Herrmann

Chairman of Scientific Advisory Board

Prof. Dr. Ken Herrmann, MD, MBA, is Chairman of Scientific Advisory Board of Molecular Partners AG from December 2025. Dr. Herrmann is Member of Research & Innovation Advisory Board of Bicycle Therapeutics plc from 2025. Dr. Herrmann serves as Chair of Scientific Advisory Board at Aktis Oncology, Inc. and serves as its Independent Director since May 2024. He served as Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee. Dr. Herrmann is Member of the Supervisory Board of Pentixapharm Holding AG from October 28, 2024. Dr. Herrmann is the Member of Scientific Advisory Board at AdvanCell Isotopes Pty Ltd. He serves as Member of Scientific Advisory Board at Radiopharm Theranostics Limited since March 2023. He served as Director of Sofie Biosciences, Inc until July 2025 and serves as Member of the Scientific Advisory Board since July 2025 and Chairman of Scientific Advisory Board. He received the MD and Doctorate from Humboldt Universität zu Berlin with his work Expression and function of A1 adenosine receptors in gliomas. In 2011 he completed the executive MBA program at Universität Zürich, Switzerland. Professor Herrmann completed his residency in Nuclear Medicine at Klinikum rechts der Isar, Technische Universität München, as well as his habilitation titled. In Vivo-Proliferation Imaging with 3´deoxy-3´-[18F]Fluorothymidine PET in Oncology“. He is a certified Nuclear Medicine physician and is one of the top Medical Expert and Key Opinion Leader in the radiopharmaceutical sector. He has exposure to radioligand therapy and has a wealth of experience in early clinical translation of novel radioligand therapy concepts. In May 2011 he joined as Visiting Assistant Professor and was later promoted to tenure track Associate Professor in the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). From August 2012 to July 2016 he served as Vice Chair of the Department of Nuclear Medicine at Universitätsklinikum Würzburg. Since August 2016 Professor Herrmann acts as Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen and as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at UCLA. He also is the Chair of the EANM Oncology & Theranostics committee and Section Editor of the Journal of Nuclear Medicine. He holds an executive MBA from the University of Zurich in 2011 and serves as Chair of the Department of Nuclear Medicine at Universitätsmedizin Essen, Germany.

Positions